Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of KBR, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its business operations and prospects during a specific class period [1]. Group 1: Allegations and Class Period - The class period for the allegations against KBR is from May 6, 2025, to June 19, 2025 [1]. - The complaint claims that KBR's management was aware of concerns from the U.S. Department of Defense regarding HomeSafe's ability to fulfill a global household goods contract but misrepresented the situation as being without issues [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased KBR shares during the specified period are encouraged to register for the class action by November 18, 2025, to potentially become lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to deceitful practices and misleading statements by companies [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its competitive position and financial guidance during a specified period [1][2]. Summary by Relevant Sections Allegations - The complaint claims that LifeMD's management overstated the company's competitive position and was reckless in raising its 2025 guidance without properly accounting for increased customer acquisition costs in its RexMD segment and related to obesity treatment drugs [1]. Class Period - The class period for the allegations is from May 7, 2025, to August 5, 2025, during which shareholders are encouraged to register for potential lead plaintiff appointment [1][2]. Next Steps for Shareholders - Shareholders who purchased shares during the specified timeframe are advised to register for the class action, which includes enrollment in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for investors who suffered losses due to misleading statements or omissions by companies [3].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) for allegedly issuing false and misleading statements regarding its drug candidate SLK during the class period from March 10, 2024, to September 29, 2025 [1]. Summary by Sections Allegations - The complaint alleges that the defendants failed to disclose that SLK and BIMZELX share the same molecular targets, specifically the inflammatory cytokines IL-17A and IL-17F [1]. - It is claimed that SLK's unique Nanobody structure would not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [1]. - The assertion is made that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy [1]. - Based on these points, the defendants are said to lack a reasonable basis for their positive statements regarding SLK's superiority to monoclonal antibodies [1]. Class Action Details - Shareholders who purchased shares of MLTX during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1]. - The deadline for shareholders to register for the class action is December 15, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Semler Scientific, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose a material investigation by the U.S. Department of Justice [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from March 10, 2021, to April 15, 2025 [2]. - Allegations include that Semler Scientific did not disclose a material investigation by the U.S. Department of Justice related to violations of the False Claims Act [2]. - The deadline for shareholders to register for the class action is October 28, 2025 [3]. Group 2: Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

https://securitiesclasslaw.com/securities/fortinet-inc-loss-submission-form/?id=173408&from=4 CLASS PERIOD: November 8, 2024 to August 6, 2025 Accessibility StatementSkip Navigation NEW YORK, Oct. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fortinet, Inc. (NASDAQ: FTNT). Shareholders who purchased shares of FTNT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not r ...

Core Points - The Gross Law Firm has issued a notice to shareholders of Cytokinetics, Incorporated regarding potential lead plaintiff appointments in a class action lawsuit related to misleading statements about the New Drug Application (NDA) for aficamten [1][2] - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, during which shareholders are encouraged to register for participation [2] - Allegations include that Cytokinetics misrepresented the timeline for FDA approval and failed to disclose risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS), leading to inflated stock prices and subsequent losses for investors when the truth was revealed [1] Company Specifics - Cytokinetics is facing legal scrutiny for allegedly making materially false and misleading statements regarding its NDA submission process for aficamten, which is critical for its market position [1] - The company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, which could have significant implications for its regulatory approval process [1] Legal Context - The Gross Law Firm is recognized for its commitment to protecting investor rights and seeks recovery for those who suffered losses due to misleading corporate practices [3] - Shareholders are advised to register by November 17, 2025, to be included in the monitoring of the case's progress [2]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during a specified class period [1][3]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from May 7, 2025, to August 5, 2025 [3]. - Allegations include that LifeMD's management overstated the company's competitive position and raised 2025 guidance without properly accounting for rising customer acquisition costs, particularly in the RexMD segment and for obesity treatment drugs like Wegovy and Zepbound [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by October 25, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Accessibility StatementSkip Navigation NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). DEADLINE: November 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/lantheus-holdings-inc-loss-submission-form-2/? id=172698&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of LNTH ...

Core Points - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [2][4] - The company's EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price from $6.03 to $1.02, a decline of 83.2% in one day [2][3] - Shareholders who purchased shares during the class period from January 16, 2025, to September 12, 2025, are encouraged to register for the class action, with a lead plaintiff deadline set for December 8, 2025 [3][4] Company Information - The Gross Law Firm is representing shareholders in the class action, emphasizing its commitment to protecting investors from deceit and fraud [4][5] - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit due to alleged misleading statements related to the approval of MOLBREEVI BLA, a treatment for pulmonary alveolar proteinosis [1][2]. Summary by Sections Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding MOLBREEVI BLA, including: - Lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls [1] - Unlikelihood of FDA approval for MOLBREEVI BLA in its current form [1] - Delay in submission of MOLBREEVI BLA within the previously represented timeframe [1] - Increased likelihood of needing to raise additional capital due to regulatory approval delays [1] - Overall, public statements made by the defendants were materially false and misleading [1]. Next Steps for Shareholders - Shareholders who purchased shares of SVRA during the specified timeframe are encouraged to register for the class action by November 7, 2025, to potentially become lead plaintiffs [2]. - Registration includes enrollment in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].